Avalon Pharmaceuticals, Inc. (AVRX)

[surf1944]

Avalon Pharmaceuticals to Present at 20th Annual Roth Capital Partners Growth Stock Conference
Thursday February 14, 8:00 am ET

GERMANTOWN, Md.--(BUSINESS WIRE)--Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX - News), today announced that C. Eric Winzer, Executive Vice President and CFO, will provide an update on the Company at the 20th Annual Roth Capital Partners Growth Stock Conference.

The conference will be held at The Ritz Carlton in Laguna Niguel, CA, February 18-21. Mr. Winzer is scheduled to present on Tuesday, February 19, at 11:00am.

About Avalon Pharmaceuticals

Avalon is a biopharmaceutical company focused on the discovery, development and commercialization of first-in-class cancer therapeutics. Avalon’s lead product candidate, AVN944, an IMPDH inhibitor, is in Phase II clinical development. Avalon also has preclinical programs to develop inhibitors of the Beta-catenin and Aurora/Centrosome pathways, discovery programs for inhibitors of the Survivin and Myc pathways and partnerships with Merck, MedImmune, ChemDiv, Medarex, and Novartis. AvalonRx® is the company’s proprietary platform which is based on large-scale biomarker identification and monitoring, used to discover and develop therapeutics for pathways that have historically been characterized as "undruggable." Avalon is headquartered in Germantown, MD.